GlassScriptPhysician profile
Colby J Mitchell
NPI 1164546701
$5,677.66
in general payments reported to CMS, 2019-2025
26 companies · $3,292 in 2025
The $3,292 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $357 · 2022: $695 · 2023: $594 · 2024: $740 · 2025: $3,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,354 · Travel and Lodging: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,354.12 |
| Travel and Lodging | $1,271.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,203.30 | 2022-2025 | Inspire |
| Genzyme Corporation | $696.50 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $691.63 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $491.06 | 2022-2025 | Nucala |
| Optinose US, INC. | $457.80 | 2021-2025 | |
| Stryker Corporation | $133.75 | 2022-2025 | Clarifix, Xpress Loprofile, Audion Et Dilation System |
| Intersect Ent, INC. | $133.68 | 2021-2022 | |
| Abbott Laboratories | $108.49 | 2025 | Freestyle Libre 3 |
| Aerin Medical INC. | $94.74 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $90.69 | 2021-2025 | Tezspire |
| Phathom Pharmaceuticals, INC. | $79.63 | 2024-2025 | Voquezna |
| Amgen INC. | $69.05 | 2024-2025 | Tavneos |
| Ars Pharmaceuticals Operations, INC. | $56.08 | 2025 | Neffy |
| Baxter Healthcare | $48.60 | 2025 | Perclot |
| Medtronic, INC. | $48.37 | 2022-2023 | Sinuva |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $43.68 | 2023 | Seglentis |
| Pfizer INC. | $32.26 | 2025 | |
| Smith+Nephew, INC. | $29.23 | 2022-2023 | Tula |
| Novartis Pharmaceuticals Corporation | $28.02 | 2025 | |
| Merck Sharp & Dohme LLC | $27.23 | 2023 | |
| Abbvie INC. | $25.15 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.84 | 2023 | Takhzyro |
| Itamar Medical INC | $18.49 | 2023 | Watchpatone |
| Lilly USA, LLC | $16.40 | 2025 | Zepbound |
| Acclarent, INC | $14.74 | 2023 | Acclarent Aera, Relieva Spinplus |
| Kaleo, INC. | $14.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colby Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.